BioCentury
ARTICLE | Clinical News

Durect completes Phase II Sufentanil trial

May 11, 2001 7:00 AM UTC

DRRX completed the clinical portion of a U.S. Phase II trial of its Duros subcutaneous sustained release device for delivery of sufentanil in over 50 patients with stable, opioid responsive, chronic p...